Showing 2321-2330 of 3329 results for "".
- Merz Americas Rolls Out New Xeomin ‘Later Haters' Campaignhttps://modernaesthetics.com/news/merz-americas-rolls-out-new-xeomin-later-haters-campaign/2471983/Merz Americas is launching a new advertising campaign for Xeomin (incobotulinumtoxinA) called “Later Haters,” which urges women to “X out” judgment, stop apologizing for caring about how they look and put an end to feeling
- Revance Shares Positive Efficacy and Duration Data for RT002https://modernaesthetics.com/news/revance-share-positive-efficacy-and-duration-data-for-rt002/2471986/Revance Therapeutics, Inc.'s long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term s
- Sinclair Pharma: Acquisition by Huadong Medicine Company Limited Now Completehttps://modernaesthetics.com/news/sinclair-pharma-acquisition-by-huadong-medicine-company-limited-now-complete/2471988/Huadong Medicine Company Limited (HMC) has acquired Sinclair Pharma Limited, a global aesthetics company headquartered in London, UK, in a deal worth approximately $222 million. HMC is a well-known Chinese pharmaceutical listed company that has established a leading aesthetics business in China a
- Novel 1060 Diode Laser Proves Safe and Effective for Hair Removalhttps://modernaesthetics.com/news/novel-1060-diode-laser-proves-safe-and-effective-for-hair-removal/2471992/A novel 1060 nm diode laser system is safe and effective for hair removal and long-term hair reduction in all skin types including darkly pigmented individuals, according to
- Bellus Recognized with Multiple Aesthetic Awardshttps://modernaesthetics.com/news/bellus-recognized-with-multiple-aesthetic-awards/2472006/Bellus Medical topped the charts in eight categories presented by the 2018 Aesthetic Everything® Awards: · Top Aesthetic Companies · Top Skin Care Devices (SkinPen&r
- Galderma Announces the Start of Six New Aesthetic Studieshttps://modernaesthetics.com/news/galderma-announces-the-start-of-six-new-aesthetic-studies/2472014/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://modernaesthetics.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2472031/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- Allergan Shares Results of Higher Dose Botox Cosmetic for the Treatment Glabellar Lineshttps://modernaesthetics.com/news/allergan-share-results-of-higher-dose-botox-cosmetic-for-the-treatment-glabellar-lines/2472035/Allergan plc clinical study results of higher doses of Botox Cosmetic compared to Botox Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines. Allergan conducted this trial to evaluate the duration of effect and safety of Botox
- With New Applicator, Cryolipolysis is an Option for Male Pseudogynecomastiahttps://modernaesthetics.com/news/withnew-applicator-cryolipolysis-is-an-option-for-male-pseudogynecomastia/2472059/Thanks to a conformable surface applicator, cryolipolysis can be a safe and effective way to treat male pseudogynecomastia, according to a recent